What the changes say
- Manufacturing resilience becomes more prominent, including CMO compliance, single-source supply, capacity, tariffs and disaster recovery.
- Regulatory and pricing risks focus more sharply on healthcare reform, government pricing programs and FDA delays.
- The filing adds development risk for RDX10531 and removes several financing, profitability and XPHOZAH-specific risks.
What changed since the prior 10-K
New
- NewRisks Related to our Financial Condition and Capital Requirements
impose on our CMOs. Although they are contractually required to do so, we are completely dependent on our CMOs for compliance with the regulatory requirements, known as cGMP requirements, for manufacture of both active drug substances and finished drug products
Dependence on CMOs creates cGMP compliance, production, quality, capacity and replacement-manufacturer risks for active ingredients and finished drugs.
- NewRisks Related to our Financial Condition and Capital Requirements
Our future business prospects may depend on our ability, alone or through our current or future collaborations, to successfully develop, gain regulatory approval of and commercialize our current and future product candidates
Developing and commercializing candidates, including the newly initiated RDX10531 program, may require lengthy trials and regulatory approval without successful results.
- NewRisks Related to our Financial Condition and Capital Requirements
single source, which exposes us to a number of risks related to our supply chain, including delivery failure and drug shortages. To date, we have no qualified alternative sources for these single source CMOs
Single-source CMOs create delivery and shortage exposure, while material price increases, tariffs, inflation and foreign suppliers could raise costs and reduce margins.
- NewRisks Related to our Financial Condition and Capital Requirements
Changes in U.S. and international trade policies may adversely impact our business and operating results
Tariffs, export controls and other changes in U.S. or international trade policy could increase manufacturing costs and disrupt API and finished-product imports or exports.
- NewRisks Related to our Financial Condition and Capital Requirements
We or the third parties upon whom we depend may be adversely affected by natural disasters, severe weather, public health emergencies and other catastrophic events, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
Natural disasters, severe weather, public health emergencies, cyber disruptions and transportation incidents could interrupt facilities, trials, sales and third-party operations.
- NewRisks Related to our Financial Condition and Capital Requirements
handling costs, and delays in manufacturing, release or crucial business timelines, any of which could materially impact our sales, financial results, patient fulfillment efforts and reputation
Business continuity plans may lack sufficient backup suppliers, distribution channels, manufacturing capacity or inventory to prevent costly fulfillment and manufacturing delays.
- NewRisks Related to Government Regulation
Current and future healthcare reform legislation, regulation or action by the current administration may increase the difficulty and cost for us to commercialize our approved products and may adversely affect the prices we, or they, may obtain and may have a negative impact on our business and results of operations
Healthcare reform and administration actions could increase commercialization costs, restrict approved-product activities and reduce prices or reimbursement.
- NewRisks Related to Intellectual Property
Moreover, any name we have proposed to use with our product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe
FDA or foreign regulators may reject proposed product names, forcing costly replacement searches and creating trademark infringement exposure.
Dropped
- DroppedRisks Related to our Financial Condition and Capital Requirements
We have incurred losses in each year since our inception, and we expect to continue to incur operating losses in the future as we incur additional expenses related to our ongoing operations and our pursuit of future business opportunities
Recurring operating losses despite commercialization of IBSRELA and XPHOZAH.
- DroppedRisks Related to our Financial Condition and Capital Requirements
We expect to continue to incur operating losses for the foreseeable future as we incur expenses related to our ongoing operations and our pursuit of future business opportunities
Future operating losses and possible insufficient liquidity to fund obligations.
- DroppedRisks Related to our Financial Condition and Capital Requirements
We have generated limited revenue from product sales and may never be profitable for a full fiscal year
- DroppedRisks Related to our Financial Condition and Capital Requirements
XPHOZAH is now included in the ESRD PPS, effective January 1, 2025, which means coverage for XPHOZAH for Medicare beneficiaries is no longer available under Medicare Part D, and as a result the revenue that we may generate on sales of XPHOZAH will be negatively and materially impacted
Limited product revenue and uncertainty about achieving full-year profitability.
- DroppedRisks Related to our Financial Condition and Capital Requirements
for our products may be reduced compared with the U.S. and may be insufficient to generate commercially reasonable revenue and profits
- DroppedRisks Related to our Financial Condition and Capital Requirements
foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or market perception of their requirements may have on our business and may not always be able to anticipate how to respond to these laws or regulations
Medicare ESRD PPS inclusion could materially reduce XPHOZAH revenue.
- DroppedRisks Related to our Financial Condition and Capital Requirements
Clinical drug development involves a lengthy and expensive process with an uncertain outcome
- DroppedRisks Related to our Financial Condition and Capital Requirements
We may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
- DroppedRisks Related to Government Regulation
We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the U.S. or abroad
Foreign and government payor coverage or reimbursement may be inadequate for products.
- DroppedRisks Related to Our Common Stock
We are no longer a “smaller reporting company” and as a result we are or will be subject to certain enhanced disclosure requirements which will require us to incur significant expenses and expend time and resources
Reworded
- 94% rewrittenRisks Related to our Financial Condition and Capital Requirements
Our future results depend on CMOs, many of whom are our single source manufacturers
The risk continues to emphasize single-source CMOs, supply disruption and price-adjustment exposure; the excerpt shows no clear substantive change.
- 83% rewrittenRisks Related to Our Common Stock
If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may decline
The dilution risk now also notes significant public-company operating costs and management time devoted to compliance initiatives.
- 64% rewrittenRisks Related to our Financial Condition and Capital Requirements
Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition
The excerpt retains the same evolving global data-protection and personal-data compliance risk without a clear substantive change.
- 60% rewrittenRisks Related to our Financial Condition and Capital Requirements
Third-party payor coverage and reimbursement status of newly commercialized products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for IBSRELA and XPHOZAH could limit our ability to market those products and decrease our ability to generate revenue
The coverage and reimbursement risk for IBSRELA and XPHOZAH is substantively unchanged; only punctuation and wording were cleaned up.
- 53% rewrittenRisks Related to Government Regulation
Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition and results of operations
The focus shifts from broad ACA and healthcare-reform uncertainty to MDRP reporting, rebates, discounts, penalties and fines.
- 44% rewrittenRisks Related to Government Regulation
Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise review and process regulatory submissions in a timely manner, which could negatively impact our business
The FDA disruption risk adds the October 1–November 12, 2025 shutdown and resulting furloughs and suspended activities.
Was: Disruptions at the U.S. FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise review and process regulatory submissions in a timely manner, which could negatively impact our business
- 41% rewrittenRisks Related to our Financial Condition and Capital Requirements
We have formed in the past, and may form in the future, collaboration partnerships, joint ventures and/or licensing arrangements, and we may not realize the benefits of such collaborations
The collaboration risk and named partners remain substantively unchanged in the provided text.
- 35% rewrittenRisks Related to our Financial Condition and Capital Requirements
Principal Risks Related to Our Business
The principal-risk summary remains substantively unchanged, continuing to center on successful IBSRELA commercialization, supply, reimbursement, effectiveness and pricing.
- 31% rewrittenRisks Related to our Financial Condition and Capital Requirements
Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited
- 27% rewrittenRisks Related to Intellectual Property
If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
- 20% rewrittenRisks Related to Government Regulation
We and our CMOs are subject to significant regulation with respect to manufacturing IBSRELA and XPHOZAH. The manufacturing facilities on which we rely may not continue to meet regulatory requirements or may not be able to meet supply demands
All 44 risk factors
Headings as the filing states them, in filing order.
Risks Related to our Financial Condition and Capital Requirements
- 01Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited31% rewritten
- 02Principal Risks Related to Our Business35% rewritten
- 03IBSRELA and/or XPHOZAH may cause undesirable side effects or have other properties that could limit the commercial success of the products
- 04Third-party payor coverage and reimbursement status of newly commercialized products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for IBSRELA and XPHOZAH could limit our ability to market those products and decrease our ability to generate revenue60% rewritten
- 05impose on our CMOs. Although they are contractually required to do so, we are completely dependent on our CMOs for compliance with the regulatory requirements, known as cGMP requirements, for manufacture of both active drug substances and finished drug productsNew
- 06Our future business prospects may depend on our ability, alone or through our current or future collaborations, to successfully develop, gain regulatory approval of and commercialize our current and future product candidatesNew
- 07Our future results depend on CMOs, many of whom are our single source manufacturers94% rewritten
- 08single source, which exposes us to a number of risks related to our supply chain, including delivery failure and drug shortages. To date, we have no qualified alternative sources for these single source CMOsNew
- 09Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement with SLR, as amended, and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business
- 10The biotechnology and pharmaceutical industries are highly competitive, and we face significant competition from companies in the biotechnology, pharmaceutical and other related markets that are researching and marketing products designed to address diseases that we are currently developing products to treat
- 11We may experience difficulties in managing our current activities and growth given our level of managerial, operational, financial and other resources
- 12We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management
- 13If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of IBSRELA and/or XPHOZAH
- 14If we fail to attract, retain and motivate our executives, senior management and key personnel, our business will suffer
- 15Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition64% rewritten
- 16We have formed in the past, and may form in the future, collaboration partnerships, joint ventures and/or licensing arrangements, and we may not realize the benefits of such collaborations41% rewritten
- 17We will rely on third parties to conduct all of our nonclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for additional products or commercialize our product candidates
- 18Changes in U.S. and international trade policies may adversely impact our business and operating resultsNew
- 19Our business involves the use of hazardous materials and we and third parties with whom we contract must comply with environmental laws and regulations, which can be expensive and restrict how we do business
- 20We or the third parties upon whom we depend may be adversely affected by natural disasters, severe weather, public health emergencies and other catastrophic events, and our business continuity and disaster recovery plans may not adequately protect us from a serious disasterNew
- 21handling costs, and delays in manufacturing, release or crucial business timelines, any of which could materially impact our sales, financial results, patient fulfillment efforts and reputationNew
Risks Related to Government Regulation
- 22Current and future healthcare reform legislation, regulation or action by the current administration may increase the difficulty and cost for us to commercialize our approved products and may adversely affect the prices we, or they, may obtain and may have a negative impact on our business and results of operationsNew
- 23Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise review and process regulatory submissions in a timely manner, which could negatively impact our business44% rewritten
- 24We and our CMOs are subject to significant regulation with respect to manufacturing IBSRELA and XPHOZAH. The manufacturing facilities on which we rely may not continue to meet regulatory requirements or may not be able to meet supply demands20% rewritten
- 25IBSRELA and/or XPHOZAH may cause or contribute to adverse medical events that we are required to report to regulatory agencies and if we fail to do so we could be subject to sanctions that would materially harm our business
- 26Our employees, independent contractors, principal investigators, CROs, collaboration partners, consultants, CMOs and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
- 27Failure to obtain regulatory approvals in foreign jurisdictions would prevent us from marketing our products internationally
- 28We and our collaboration partners are subject to healthcare laws, regulation and enforcement; our failure or the failure of any such collaboration partners to comply with these laws could have a material adverse effect on our results of operations and financial conditions
- 29Legislative or regulatory healthcare reforms in the U.S. may make it more difficult and costly for us to obtain regulatory clearance or approval of our product candidates and to produce, market and distribute our products after clearance or approval is obtained
- 30Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition and results of operations53% rewritten
Risks Related to Intellectual Property
- 31Our success will depend on our ability to obtain, maintain and protect our intellectual property rights
- 32If we are not able to successfully enforce our intellectual property rights, the commercial value of IBSRELA and XPHOZAH or other product candidates may be adversely affected and we may not be able to compete effectively in our market
- 33We may not be able to enforce our intellectual property rights throughout the world
- 34If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed
- 35If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected27% rewritten
- 36Moreover, any name we have proposed to use with our product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in EuropeNew
- 37We may be subject to claims that we or our employees have misappropriated the intellectual property, including know-how or trade secrets, of a third party, or claiming ownership of what we regard as our own intellectual property
Risks Related to Our Common Stock
- 38Our stock price may continue to be volatile and our stockholders may not be able to resell shares of our common stock at or above the price they paid
- 39If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may decline83% rewritten
- 40We may be adversely affected by the global economic environment
- 41Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management
- 42In addition, these provisions would apply even if we were to receive an offer that some stockholders may consider beneficial
- 43Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law
- 44We do not currently intend to pay dividends on our common stock, and, consequently, our stockholders’ ability to achieve a return on their investment will depend on appreciation in the price of our common stock
Other Ardelyx 10-Ks
- FY2024 10-K risk factors46 risks
Ardelyx faces heavy concentration risk around the commercial success of its only two products, IBSRELA and XPHOZAH. Medicare coverage changes for XPHOZAH under the ESRD PPS threaten future revenues. Operations depend heavily on single-source contract manufacturers.
Filed Feb 20, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.